Please ensure Javascript is enabled for purposes of website accessibility

Why Boston Scientific Shares Fell 12.7% in March

By Adria Cimino - Updated Apr 3, 2020 at 8:56AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus outbreak meant the postponement of medical procedures, weighing on Boston Scientific’s revenue.

What happened

Shares of Boston Scientific (BSX -0.53%) slipped 12.7% in March, according to data provided by S&P Global Market Intelligence, as investors anticipated a slowdown in its business due to the outbreak of COVID-19, the illness caused by the novel coronavirus.

Boston Scientific, a maker of devices such as stents and catheters, on Feb. 5 -- when the health crisis remained primarily in China -- predicted delayed medical procedures and supply chain disruptions would hurt business there. At that time, the company estimated the coronavirus in China could have a $10 million to $40 million negative impact on its sales in the first quarter.

Four surgeons are at work in an operating room.

Image source: Getty Images.

So what

Now that the coronavirus outbreak has expanded, reaching 900,300 cases worldwide, delayed procedures have become a problem for Boston Scientific in countries beyond China. To handle the influx of coronavirus patients, hospitals have postponed non-essential elective procedures. This results in a clear weight on Boston Scientific's revenue prospects for the quarter.

Now what

Boston Scientific provided an update on April 2, saying procedure volumes dropped "significantly" last month as COVID-19 cases climbed. As a result, the company now expects first-quarter revenue growth to be flat to slightly up on a GAAP basis year over year. Boston Scientific predicts a 2% to 3% decline in organic revenue for the period. In an effort to cut costs in case the outbreak continues, all executive officers are taking a pay cut that could last up to six months. Chief executive officer Michael Mahoney is forgoing his base salary, while the other executives are taking a 50% pay cut.

Though the immediate picture looks grim for Boston Scientific, the shares remain a strong bet for the long-term investor due to a track record of increasing annual revenue -- and the promise of newly approved products like the Exalt Model D duodenoscope. Duodenoscopes are used in procedures performed 1.5 million times globally every year to explore pancreatic and bile ducts and treat related conditions. Some investors may use weakness in Boston Scientific now to take a position in the stock and benefit from future revenue growth.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Boston Scientific Corporation Stock Quote
Boston Scientific Corporation
$37.82 (-0.53%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.